Spots Global Cancer Trial Database for Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors
Official Title: A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) Administered Once Every Three Weeks in Patients With Advanced Solid Tumors
Study ID: NCT00069277
Conditions
Interventions
Study Description
Brief Summary: The malignancies (advanced solid tumors) that have been chosen for evaluation of E7389 are those where E7389 has demonstrated significant pre-clinical anti-tumor activity, both in vitro and in vivo. The ultimate goal is to demonstrate the clinical activity of E7389 in the treatment of these, and potentially other, tumor types.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Institute Medical Group, Los Angeles, California, United States
Premiere Oncology, Santa Monica, California, United States
, New Brunswick, New Jersey, United States
Contact Details
Name: Dale Schuster, Ph.D
Affiliation: Eisai Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
